BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 29203375)

  • 1. Spatial and temporal alterations in protein structure by EGF regulate cryptic cysteine oxidation.
    Behring JB; van der Post S; Mooradian AD; Egan MJ; Zimmerman MI; Clements JL; Bowman GR; Held JM
    Sci Signal; 2020 Jan; 13(615):. PubMed ID: 31964804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Free energy calculations on the stability of the 14-3-3ζ protein.
    Jandova Z; Trosanova Z; Weisova V; Oostenbrink C; Hritz J
    Biochim Biophys Acta Proteins Proteom; 2018 Mar; 1866(3):442-450. PubMed ID: 29203375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cysteine Modification by Ebselen Reduces the Stability and Cellular Levels of 14-3-3 Proteins.
    Waløen K; Jung-Kc K; Vecchia ED; Pandey S; Gasparik N; Døskeland A; Patil S; Kleppe R; Hritz J; Norton WHJ; Martinez A; Haavik J
    Mol Pharmacol; 2021 Aug; 100(2):155-169. PubMed ID: 34031189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of protein stabilization by disulfide bridges: calorimetric unfolding studies on disulfide-deficient mutants of the alpha-amylase inhibitor tendamistat.
    Vogl T; Brengelmann R; Hinz HJ; Scharf M; Lötzbeyer M; Engels JW
    J Mol Biol; 1995 Dec; 254(3):481-96. PubMed ID: 7490764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of salt bridges in the dimer interface of 14-3-3ζ in dimer dynamics, N-terminal α-helical order, and molecular chaperone activity.
    Woodcock JM; Goodwin KL; Sandow JJ; Coolen C; Perugini MA; Webb AI; Pitson SM; Lopez AF; Carver JA
    J Biol Chem; 2018 Jan; 293(1):89-99. PubMed ID: 29109150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thermodynamic Stability of Human γD-Crystallin Mutants Using Alchemical Free-Energy Calculations.
    Aguayo-Ortiz R; González-Navejas A; Palomino-Vizcaino G; Rodriguez-Meza O; Costas M; Quintanar L; Dominguez L
    J Phys Chem B; 2019 Jul; 123(27):5671-5677. PubMed ID: 31199646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical residue that promotes protein dimerization: a story of partially exposed Phe25 in 14-3-3σ.
    Liu JY; Li Z; Li H; Zhang JT
    J Chem Inf Model; 2011 Oct; 51(10):2612-25. PubMed ID: 21870863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the binding pathways of the 14-3-3ζ protein: Structural and free-energy profiles revealed by Hamiltonian replica exchange molecular dynamics with distancefield distance restraints.
    Nagy G; Oostenbrink C; Hritz J
    PLoS One; 2017; 12(7):e0180633. PubMed ID: 28727767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissection of binding between a phosphorylated tyrosine hydroxylase peptide and 14-3-3zeta: A complex story elucidated by NMR.
    Hritz J; Byeon IJ; Krzysiak T; Martinez A; Sklenar V; Gronenborn AM
    Biophys J; 2014 Nov; 107(9):2185-94. PubMed ID: 25418103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The key to predicting the stability of protein mutants lies in an accurate description and proper configurational sampling of the folded and denatured states.
    Eichenberger AP; van Gunsteren WF; Riniker S; von Ziegler L; Hansen N
    Biochim Biophys Acta; 2015 May; 1850(5):983-995. PubMed ID: 25239199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into conformational change for 14-3-3σ protein by molecular dynamics simulation.
    Hu G; Li H; Liu JY; Wang J
    Int J Mol Sci; 2014 Feb; 15(2):2794-810. PubMed ID: 24552877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Net charge changes in the calculation of relative ligand-binding free energies via classical atomistic molecular dynamics simulation.
    Reif MM; Oostenbrink C
    J Comput Chem; 2014 Jan; 35(3):227-43. PubMed ID: 24249099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of 14-3-3-ζ Interactions with integrin tails.
    Bonet R; Vakonakis I; Campbell ID
    J Mol Biol; 2013 Sep; 425(17):3060-72. PubMed ID: 23763993
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.